Brief: Atea Pharmaceuticals' Board Of Directors Unanimously Rejects Unsolicited Proposal From Tang Capital Partners' Affiliate Concentra Biosciences
30/05/2023 12:46
May 30 (Reuters) - Atea Pharmaceuticals Inc AVIR.O :
* ATEA PHARMACEUTICALS’ BOARD OF DIRECTORS UNANIMOUSLY
REJECTS
UNSOLICITED PROPOSAL FROM TANG CAPITAL PARTNERS’ AFFILIATE,
CONCENTRA BIOSCIENCES
* ATEA PHARMACEUTICALS INC - BOARD UNANIMOUSLY REJECTED
UNSOLICITED PROPOSAL FROM TANG CAPITAL PARTNERS, LP ON BEHALF OF
CONCENTRA BIOSCIENCES
* ATEA PHARMACEUTICALS INC - BOARD UNANIMOUSLY CONCLUDED
THAT
PROPOSAL FUNDAMENTALLY UNDERVALUES CO
Source text for Eikon: ID:nGNX2L07J8
Further company coverage: AVIR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atea Pharmaceuticals
See all newsAtea Pharmaceuticals Q2 loss narrows as HCV trial expenses decline
Atea Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
NASDAQ RESUMED AT 07:30 AM